^
    Apply
    Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer (NCI-2018-01296) (NCT02983578)
    Phase 2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    08/27/2024
    Initiation :
    03/02/2017
    Primary completion :
    04/30/2025
    Completion :
    04/30/2025
    CD8 • STAT3
    |
    PD-L1 expression • STAT3 expression
    |
    Imfinzi (durvalumab) • danvatirsen (AZD9150)
    Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML (NCT05986240)
    Phase 1
    Montefiore Medical Center
    Recruiting
    Last update posted :
    06/12/2024
    Initiation :
    05/08/2024
    Primary completion :
    10/01/2025
    Completion :
    07/01/2028
    BCL2
    |
    Venclexta (venetoclax) • danvatirsen (AZD9150)
    Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC (PEMDA-HN) (NCT05814666)
    Phase 2
    Flamingo Therapeutics NV
    Recruiting
    Last update posted :
    05/31/2024
    Initiation :
    05/30/2023
    Primary completion :
    05/30/2025
    Completion :
    05/30/2026
    PD-L1
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • danvatirsen (AZD9150)
    Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer (BISCAY) (NCT02546661)
    Phase 1
    AstraZeneca
    Active, not recruiting
    Last update posted :
    03/12/2024
    Initiation :
    10/03/2016
    Primary completion :
    03/18/2020
    Completion :
    06/28/2024
    HRD • CDKN2A • RB1 • FGFR • CD8 • CCNE1 • MYCN • IFNG • IL6 • IL2 • IL10 • MYCL
    |
    PD-L1 expression • FGFR3 mutation • CDKN2A deletion • CCNE1 amplification • CDKN2A mutation • FGFR fusion • RB1 deletion • MYCL amplification
    |
    Lynparza (olaparib) • Imfinzi (durvalumab) • Koselugo (selumetinib) • adavosertib (AZD1775) • fexagratinib (ABSK091) • vistusertib (AZD2014) • danvatirsen (AZD9150)
    A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC (MAGELLAN) (NCT03819465)
    Phase 1
    AstraZeneca
    Active, not recruiting
    Last update posted :
    02/28/2024
    Initiation :
    12/27/2018
    Primary completion :
    05/23/2023
    Completion :
    03/26/2026
    EGFR • PD-L1 • ALK
    |
    EGFR mutation • ALK fusion
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • gemcitabine • albumin-bound paclitaxel • pemetrexed • oleclumab (MEDI9447) • rilvegostomig (AZD2936) • volrustomig (MEDI5752) • danvatirsen (AZD9150)
    Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers (NCT01563302)
    Phase 1/2
    Ionis Pharmaceuticals, Inc.
    Completed
    Last update posted :
    06/25/2018
    Initiation :
    02/27/2012
    Primary completion :
    03/23/2016
    Completion :
    03/23/2016
    STAT3
    |
    danvatirsen (AZD9150)